Beverly Hills, CA14 Active Studies

Lung Cancer Clinical Trials in Beverly Hills, CA

Find 14 actively recruiting lung cancer clinical trials in Beverly Hills, CA. Connect with local research sites and explore new treatment options.

14
Active Trials
9
Sponsors
7,141
Enrolling

Recruiting Lung Cancer Studies in Beverly Hills

RecruitingBeverly Hills, CANCT06311721

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®)....

927 participants
Amgen
View Study Details
RecruitingBeverly Hills, CANCT06692738

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squam...

880 participants
AstraZeneca
View Study Details
RecruitingBeverly Hills, CANCT06627647

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatmen...

878 participants
AstraZeneca
View Study Details
RecruitingBeverly Hills, CANCT06312137

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypo...

780 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingBeverly Hills, CANCT06357533

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy ...

675 participants
AstraZeneca
View Study Details
RecruitingBeverly Hills, CANCT06345729

A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

This is a study evaluating the efficacy and safety of MK-1084 with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ide...

600 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingBeverly Hills, CANCT06892548

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecifi...

594 participants
BioNTech SE
View Study Details
RecruitingBeverly Hills, CANCT06151574

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any...

416 participants
Boehringer Ingelheim
View Study Details
RecruitingBeverly Hills, CANCT06616584

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cel...

378 participants
SWOG Cancer Research Network
View Study Details
RecruitingBeverly Hills, CANCT06472245

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 a...

363 participants
OSE Immunotherapeutics
View Study Details
RecruitingBeverly Hills, CANCT06008093

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC pat...

280 participants
AstraZeneca
View Study Details
RecruitingBeverly Hills, CANCT04919811

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC....

224 participants
Nuvation Bio Inc.
View Study Details
RecruitingBeverly Hills, CANCT05456256

A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker patient population. The primary objectives of this stu...

90 participants
Lantern Pharma Inc.
View Study Details
RecruitingBeverly Hills, CANCT06031688

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first s...

56 participants
SWOG Cancer Research Network
View Study Details

About Lung Cancer Clinical Trials in Beverly Hills

Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.

There are currently 14 lung cancer clinical trials recruiting participants in Beverly Hills, CA. These studies are seeking a combined 7,141 participants. Research is being sponsored by Amgen, AstraZeneca, Merck Sharp & Dohme LLC and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lung Cancer Clinical Trials in Beverly Hills — FAQ

Are there lung cancer clinical trials in Beverly Hills?

Yes, there are 14 lung cancer clinical trials currently recruiting in Beverly Hills, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Beverly Hills?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Beverly Hills research site will contact you about next steps.

Are clinical trials in Beverly Hills free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Beverly Hills studies also compensate for your time and travel.

What lung cancer treatments are being tested?

The 14 active trials in Beverly Hills are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.

Data updated March 2, 2026 from ClinicalTrials.gov